AU2006304868B2 - Method of treating clostridium difficile-associated diarrhea - Google Patents

Method of treating clostridium difficile-associated diarrhea Download PDF

Info

Publication number
AU2006304868B2
AU2006304868B2 AU2006304868A AU2006304868A AU2006304868B2 AU 2006304868 B2 AU2006304868 B2 AU 2006304868B2 AU 2006304868 A AU2006304868 A AU 2006304868A AU 2006304868 A AU2006304868 A AU 2006304868A AU 2006304868 B2 AU2006304868 B2 AU 2006304868B2
Authority
AU
Australia
Prior art keywords
mixture
mcc
tiacumicin
weight
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006304868A
Other languages
English (en)
Other versions
AU2006304868A1 (en
Inventor
Farah Babakhani
Yu-Hung Chiu
Sherwood Gorbach
Thomas John Louie
Starr Louise Miller-Shangle
Alex Romero
Pamela Sears
Youe-Kong Shue
Robert Brian Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2006304868A1 publication Critical patent/AU2006304868A1/en
Application granted granted Critical
Publication of AU2006304868B2 publication Critical patent/AU2006304868B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request for Assignment Assignors: OPTIMER PHARMACEUTICALS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006304868A 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea Ceased AU2006304868B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Publications (2)

Publication Number Publication Date
AU2006304868A1 AU2006304868A1 (en) 2007-04-26
AU2006304868B2 true AU2006304868B2 (en) 2013-02-21

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006304868A Ceased AU2006304868B2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Country Status (7)

Country Link
EP (1) EP1940417A4 (enExample)
JP (1) JP2009512691A (enExample)
KR (1) KR101399621B1 (enExample)
CN (2) CN101340919B (enExample)
AU (1) AU2006304868B2 (enExample)
CA (1) CA2626698C (enExample)
WO (1) WO2007048059A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP4242295B1 (en) * 2018-06-07 2024-08-28 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2005112990A2 (en) * 2004-05-14 2005-12-01 Optimer Pharmaceuticals, Inc. Treatment of diseases associated with the use of antibiotics
WO2006085838A1 (en) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
WO2004014295A2 (en) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2005112990A2 (en) * 2004-05-14 2005-12-01 Optimer Pharmaceuticals, Inc. Treatment of diseases associated with the use of antibiotics
WO2006085838A1 (en) * 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof

Also Published As

Publication number Publication date
CA2626698A1 (en) 2007-04-26
CA2626698C (en) 2015-12-01
WO2007048059A3 (en) 2007-05-31
EP1940417A4 (en) 2010-07-07
CN101340919B (zh) 2011-12-07
CN101340919A (zh) 2009-01-07
EP1940417A2 (en) 2008-07-09
CN102503994A (zh) 2012-06-20
KR101399621B1 (ko) 2014-06-18
HK1126410A1 (en) 2009-09-04
JP2009512691A (ja) 2009-03-26
KR20080064177A (ko) 2008-07-08
WO2007048059A2 (en) 2007-04-26
AU2006304868A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
Eykyn et al. Metronidazole and anaerobic sepsis.
AU2009308180B2 (en) Methods for treating gastrointestinal diseases
EP2222309B1 (en) Antibiotic macrocycle compounds and methods of manufacture and use thereof
US20130274175A1 (en) Treatment of disease associated with the use of antibiotics
CN101128114B (zh) 18元环大环化合物及其类似物
AU2006304868B2 (en) Method of treating clostridium difficile-associated diarrhea
JP2019514952A (ja) ９−アミノメチルミノサイクリン化合物及び尿路感染症（ｕｔｉ）の処置におけるその使用方法
Citron et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection
Bäckström et al. Effect of ceftobiprole on the normal human intestinal microflora
CN101822675B (zh) 阿朴菲类生物碱、氧代阿朴菲类生物碱及它们的衍生物在制备抗细菌药物中的应用
Alonso et al. Plasma and peritoneal ceftriaxone concentrations after intraperitoneal administration in horses with septic peritonitis
Bernabe et al. Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis
HK1126410B (en) Method of treating clostridium difficile-associated diarrhea
Rox et al. Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models
CN120154605B (zh) 去氢钩藤碱在制备降低多黏菌素毒性药物中的应用
Borgonovi et al. P794 The efficacy of ceftazidime combined with NXL104, a novel β-lactamase inhibitor, in a mouse model of kidney infections induced by β-lactamase producing Enterobacteriaceae
US20240066022A1 (en) Diiodohydroxyquinoline for the treatment of clostridium difficile infection
CN111249296B (zh) 一种抗真菌的药物组合物及互动抗真菌活性测定方法
CN120837462A (zh) 柠檬烯在制备抑制金黄色葡萄球菌异质性耐药的试剂中的应用
Nchang PELAMA PELAMA TIOGO ARNAUD

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MERCK SHARP & DOHME CORP.

Free format text: FORMER OWNER WAS: OPTIMER PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired